You are here

Article info

Article menu

Download PDFPDF

Research paper
IQOS: examination of Philip Morris International’s claim of reduced exposure

Authors

  • Gideon St.Helen Division of Clinical Pharmacology, Department of Medicine, University of California San Francisco, San Francisco, California, USA Center for Tobacco Control Research and Education, University of California, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Peyton Jacob III Division of Clinical Pharmacology, Department of Medicine, University of California San Francisco, San Francisco, California, USA Center for Tobacco Control Research and Education, University of California, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Natalie Nardone Division of Clinical Pharmacology, Department of Medicine, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  • Neal L Benowitz Division of Clinical Pharmacology, Department of Medicine, University of California San Francisco, San Francisco, California, USA Center for Tobacco Control Research and Education, University of California, San Francisco, California, USA Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Gideon St.Helen, Division of Clinical Pharmacology and Experimental Therapeutics, University of California San Francisco, San Francisco, CA 94143-1220, USA; Gideon.StHelen{at}ucsf.edu
View Full Text

Citation

St.Helen G, Jacob III P, Nardone N, et al
IQOS: examination of Philip Morris International’s claim of reduced exposure
Tobacco Control 2018;27:s30-s36.

Publication history

  • Received February 16, 2018
  • Revised June 6, 2018
  • Accepted June 16, 2018
  • First published August 29, 2018.
Online issue publication 
November 17, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.